OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis
Nenny Agustanti, Nanny Natalia Mulyani Soetedjo, Fachreza Aryo Damara, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 5, pp. 102780-102780
Closed Access | Times Cited: 18
Nenny Agustanti, Nanny Natalia Mulyani Soetedjo, Fachreza Aryo Damara, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 5, pp. 102780-102780
Closed Access | Times Cited: 18
Showing 18 citing articles:
Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
Jingli Gao, Yuhao Li, Yijun Zhang, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 5
Open Access | Times Cited: 11
Jingli Gao, Yuhao Li, Yijun Zhang, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 5
Open Access | Times Cited: 11
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 9
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 9
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Niki Katsiki, Genovefa Kolovou, Michal Vrablı́k
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Niki Katsiki, Genovefa Kolovou, Michal Vrablı́k
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis, Maria Chondrogianni, Θεόδωρος Ανδρουτσάκος, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 324-324
Open Access | Times Cited: 1
Marios Zisis, Maria Chondrogianni, Θεόδωρος Ανδρουτσάκος, et al.
Biomolecules (2025) Vol. 15, Iss. 3, pp. 324-324
Open Access | Times Cited: 1
Clinical outcomes of MAFLD versus NAFLD : A meta‐analysis of observational studies
Grazia Pennisi, G. Infantino, Ciro Celsa, et al.
Liver International (2024) Vol. 44, Iss. 11, pp. 2939-2949
Open Access | Times Cited: 8
Grazia Pennisi, G. Infantino, Ciro Celsa, et al.
Liver International (2024) Vol. 44, Iss. 11, pp. 2939-2949
Open Access | Times Cited: 8
Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study
Chao Cen, Zhongwen Fan, Xinjiang Ding, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Chao Cen, Zhongwen Fan, Xinjiang Ding, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1129-1141
Closed Access | Times Cited: 5
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1129-1141
Closed Access | Times Cited: 5
Intestinal Activation of LXRα Counteracts Metabolic-Associated Steatohepatitis Features in Mice
Gessica Lioci, Fabio Gurrado, Nadia Panera, et al.
Nutrients (2025) Vol. 17, Iss. 8, pp. 1349-1349
Open Access
Gessica Lioci, Fabio Gurrado, Nadia Panera, et al.
Nutrients (2025) Vol. 17, Iss. 8, pp. 1349-1349
Open Access
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 4, pp. 962-964
Open Access | Times Cited: 3
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 4, pp. 962-964
Open Access | Times Cited: 3
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
Danielle Adebayo, Florence Wong
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 10, pp. 1196-1211
Open Access | Times Cited: 2
Danielle Adebayo, Florence Wong
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 10, pp. 1196-1211
Open Access | Times Cited: 2
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier
Ashok Choudhury, Ruveena Bhavani Rajaram, Shiv Kumar Sarin
Hepatology International (2024) Vol. 18, Iss. S2, pp. 941-958
Closed Access | Times Cited: 2
Ashok Choudhury, Ruveena Bhavani Rajaram, Shiv Kumar Sarin
Hepatology International (2024) Vol. 18, Iss. S2, pp. 941-958
Closed Access | Times Cited: 2
Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
Salvador Benlloch, Francesc Moncho, José Luis Górriz
Nefrología (English Edition) (2024) Vol. 44, Iss. 2, pp. 129-138
Open Access | Times Cited: 1
Salvador Benlloch, Francesc Moncho, José Luis Górriz
Nefrología (English Edition) (2024) Vol. 44, Iss. 2, pp. 129-138
Open Access | Times Cited: 1
Nonalcoholic or metabolic-associated fatty liver disease and colorectal polyps: evidence from meta-analysis and two-sample Mendelian randomization
Dong Zhai, Sumei Xu, Haoge Liu, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 1
Dong Zhai, Sumei Xu, Haoge Liu, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 1
Epicardial and liver fat implications in albuminuria: a retrospective study
Carolina M. Perdomo, Nerea Martín‐Calvo, Ana Ezponda, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Carolina M. Perdomo, Nerea Martín‐Calvo, Ana Ezponda, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies
W.T. Liu, Xiaoying Sun
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access
W.T. Liu, Xiaoying Sun
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access
Néphropathies au cours des maladies hépatiques
Nassim Kamar
EMC - Hépatologie (2024) Vol. 39, Iss. 3, pp. 1-6
Closed Access
Nassim Kamar
EMC - Hépatologie (2024) Vol. 39, Iss. 3, pp. 1-6
Closed Access
Interleukin-mediated therapies in liver diseases and comorbidity effects
Nouhoum Bouare, Jean Delwaide
World Journal of Hepatology (2024) Vol. 16, Iss. 7, pp. 980-989
Open Access
Nouhoum Bouare, Jean Delwaide
World Journal of Hepatology (2024) Vol. 16, Iss. 7, pp. 980-989
Open Access
Esteatosis hepática metabólica y nefropatía diabética: una llamada a la acción
Salvador Benlloch, Francesc Moncho, José Luis Górriz
Nefrología (2023) Vol. 44, Iss. 2, pp. 129-138
Open Access
Salvador Benlloch, Francesc Moncho, José Luis Górriz
Nefrología (2023) Vol. 44, Iss. 2, pp. 129-138
Open Access
